- Novartis AG (NYSE:NVS) reported EPS of $2.42, beating estimates and showcasing a revenue of $14.05 billion, surpassing expectations.
- The company’s optimistic full-year earnings forecast is attributed to the success of its breast cancer drug, Kisqali, alongside double-digit sales growth and a significant increase in core operating income.
- Novartis announced a share buyback plan of up to $10 billion by the end of 2027, reflecting confidence in its financial health and future prospects.
Novartis AG, listed as NYSE:NVS, is a leading global healthcare company known for its innovative medicines. The company operates in the pharmaceutical sector, focusing on areas such as oncology, immunology, and neuroscience. Novartis competes with other pharmaceutical giants like Pfizer and Roche. On July 17, 2025, Novartis reported earnings per share (EPS) of $2.42, surpassing the estimated $2.38, and revenue of approximately $14.05 billion, exceeding the estimated $13.94 billion.
The company’s strong performance in the second quarter of 2025 has led to a slight increase in its earnings forecast for the year. Novartis attributes this optimistic outlook to the robust growth of its breast cancer drug, Kisqali, which significantly contributed to the positive financial projection. The company reported a double-digit sales growth of 11% in constant currency and 12% in USD, with core operating income surging by 21% in constant currency and 20% in USD.
Key products such as Kisqali, Entresto, Kesimpta, Scemblix, Leqvio, and Pluvicto drove this growth, with Kisqali alone seeing a 64% increase. The core operating income margin reached 42.2%, marking an increase of 340 basis points, largely due to higher net sales. Operating income for the quarter grew by 25% in constant currency and 21% in USD, while net income rose by 26% in constant currency and 24% in USD.
Novartis also achieved significant innovation milestones, including a positive readout from the Pluvicto Phase III PSMAddition study in PSMA+ mHSPC and FDA accelerated approval for Vanrafia for IgAN. Looking ahead, Novartis has raised its full-year 2025 guidance for core operating income, expecting it to grow in the low teens. The company plans a share buyback of up to $10 billion by the end of 2027.
Financially, Novartis has a price-to-earnings (P/E) ratio of approximately 18.12, indicating the market’s valuation of its earnings. The price-to-sales ratio stands at about 4.42, reflecting the market’s valuation of its revenue. The enterprise value to sales ratio is roughly 4.88, and the enterprise value to operating cash flow ratio is approximately 13.58, providing insight into its valuation relative to its cash flow. The debt-to-equity ratio is approximately 0.81, suggesting a moderate level of debt relative to equity, while the current ratio is about 0.79, indicating the company’s ability to cover its short-term liabilities with its short-term assets.
